Daiichi-Sankyo’s new combination form approved by KFDA

Published: 2012-09-18 06:57:00

Updated: 2012-09-18 06:57:00

Daiichi-Sankyo Korea said Sunday it has received approval from the Korea Food and Drug Administration to market Servicar HCT, a new combination treatments containing three drugs.

Sevikar HCT is a single pill, fixed-dose triple combination of three anti-hypertensive agents indicated for the tre...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK